In DepthBiomedicine

A new cancer immunotherapy suffers a setback

See allHide authors and affiliations

Science  11 May 2018:
Vol. 360, Issue 6389, pp. 588
DOI: 10.1126/science.360.6389.588

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed.  Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Enter the characters shown in the image.

Vertical Tabs

  • Indoleamine 2,3-dioxygenase inhibition in cancer immunotherapy; still a black-box

    Clinical trials with indoleamine 2,3-dioxygenase (IDO) inhibitors in cancer immunotherapy were initially failed (1). The comment of the professor Michael Platten that IDO is still a black box was very purposeful.
    Generally, IDO is thought to suppress T-cell immune response by acting on two systems. The tryptophan degradation product kynurenine activates aryl-hydrocarbon receptor (AhR), which promotes T-cell differentiation towards a regulatory phenotype (2). In parallel, in the microenvironment of the immune response tryptophan depletion activates general control non-derepressible 2 kinase (GCN2K), which decreases T-cell proliferation and induces T-cell apoptosis (3). However, most of these conclusions were extrapolated under the strictly controlled conditions of cell cultures.
    When a free fatty acid is added in the culture medium, the trend for T-cell differentiation towards a regulatory phenotype is not altered, but the anti-proliferative and pro-apoptotic properties of IDO disappear (4). The reason relies on the effect of IDO on T-cell metabolism. Depletion of tryptophan by activating GCN2K decreases glucose and glutamine catabolism. However, kynurenine by activating AhR increases free fatty acid β-oxidation, which refuels T-cells with energy, allowing their proliferation and preventing their apoptosis (5). According to these results, two of the three ways by which IDO is supposed to suppress T-cell-mediated immune response may not take place in the cancer...

    Show More
    Competing Interests: None declared.